NFKB1 and cancer: NFκB mediates crosstalk between inflammatory signals and cancer at multiple levels and there is emerging in vivo evidence that inhibiting NFκB signalling can elicit an antitumour immune response and can even enhance the effects of immune checkpoint inhibitors (Hayakawa et al., 2014).